Lilly adds AurKa Pharma to oncology buying spree

Lilly makes another purchase to boost its oncology pipeline by buying AurKa Pharma.
AurKa Pharma is currently studying drug AK-O1 in Phase 1 clinical trials, and Lilly can see the potential in the development of the drug and an opportunity for them to get ahead within the oncology division.
“Lilly Oncology is focused on the development of innovative cancer therapies that can make a meaningful difference for patients,” said Levi Garraway, senior vice president, global development and medical affairs, Lilly Oncology.
“The acquisition of AurKa Pharma expands our pipeline with a promising oncology compound targeting a distinct cell cycle pathway. The work done by AurKa will allow Lilly to leverage emerging data about cancers in which this molecule might be effective, and determine if it can be beneficial to people living with various forms of cancer.”